{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:01:46Z","timestamp":1790755306632,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":43,"publisher":"Springer US","isbn-type":[{"value":"9781071656068","type":"print"},{"value":"9781071656075","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2027]]},"DOI":"10.1007\/978-1-0716-5607-5_11","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:50Z","timestamp":1790754410000},"page":"145-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Flow Cytometric Testing in Chronic Lymphocytic Leukemia"],"prefix":"10.1007","author":[{"given":"Nadia","family":"Nasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"11_CR1","unstructured":"Campo E et al (2017) Chronic lymphocytic leukemia\/small lymphocytic lymphoma. In: Swerdlow SH et al (eds) WHO classification of tumours of hematopoietic and lymphoid tissues. IARC, Lyon, pp 216\u2013221"},{"issue":"1","key":"11_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","volume":"37","author":"B Falini","year":"2023","unstructured":"Falini B, Martino G, Lazzi S (2023) A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia 37(1):18\u201334","journal-title":"Leukemia"},{"issue":"7","key":"11_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R  et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"11","key":"11_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E  et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 140(11):1229\u20131253","journal-title":"Blood"},{"issue":"12","key":"11_CR5","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1080\/10428194.2022.2092857","volume":"63","author":"C Tang","year":"2022","unstructured":"Tang C  et al (2022) Monoclonal B-cell lymphocytosis\u2014a review of diagnostic criteria, biology, natural history, and clinical management. Leuk Lymphoma 63(12):2795\u20132806","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"11_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1056\/NEJMoa075290","volume":"359","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC  et al (2008) Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359(6):575\u2013583","journal-title":"N Engl J Med"},{"issue":"22","key":"11_CR7","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1182\/blood-2012-12-471698","volume":"121","author":"A Vardi","year":"2013","unstructured":"Vardi A  et al (2013) Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 121(22):4521\u20134528","journal-title":"Blood"},{"issue":"25","key":"11_CR8","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1182\/blood-2011-05-357251","volume":"118","author":"C Fazi","year":"2011","unstructured":"Fazi C  et al (2011) General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 118(25):6618\u20136625","journal-title":"Blood"},{"issue":"7","key":"11_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3324\/haematol.2017.183954","volume":"103","author":"I Criado","year":"2018","unstructured":"Criado I  et al (2018) Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica 103(7):1198\u20131208","journal-title":"Haematologica"},{"issue":"1","key":"11_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.b.21595","volume":"94","author":"AC Rawstron","year":"2018","unstructured":"Rawstron AC  et al (2018) Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 94(1):121\u2013128","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"11_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC  et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21(5):956\u2013964","journal-title":"Leukemia"},{"issue":"4","key":"11_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/cyto.b.20423","volume":"74","author":"E Ahmad","year":"2008","unstructured":"Ahmad E  et al (2008) Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. Cytometry B Clin Cytom 74(4):221\u2013226","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"11_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1309\/4AGUT3LKEURD7T7K","volume":"119","author":"B Kampalath","year":"2003","unstructured":"Kampalath B, Barcos MP, Stewart C (2003) Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Am J Clin Pathol 119(6):824\u2013832","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"11_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cyto.10131","volume":"50","author":"DW Kingma","year":"2002","unstructured":"Kingma DW  et al (2002) CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms. Cytometry 50(5):243\u2013248","journal-title":"Cytometry"},{"issue":"6","key":"11_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN  et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840\u20131847","journal-title":"Blood"},{"issue":"8","key":"11_CR16","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1080\/10428194.2021.1894641","volume":"62","author":"J Balakrishna","year":"2021","unstructured":"Balakrishna J  et al (2021) Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. Leuk Lymphoma 62(8):1828\u20131839","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"11_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.leu.2402339","volume":"16","author":"J Durig","year":"2002","unstructured":"Durig J  et al (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16(1):30\u201335","journal-title":"Leukemia"},{"issue":"3","key":"11_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","volume":"99","author":"TJ Hamblin","year":"2002","unstructured":"Hamblin TJ  et al (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99(3):1023\u20131029","journal-title":"Blood"},{"issue":"7","key":"11_CR19","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1182\/blood.V95.7.2455","volume":"95","author":"TJ Hamblin","year":"2000","unstructured":"Hamblin TJ  et al (2000) Immunoglobulin V genes and CD38 expression in CLL. Blood 95(7):2455\u20132457","journal-title":"Blood"},{"issue":"6","key":"11_CR20","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1182\/blood.V97.6.1892","volume":"97","author":"U Thunberg","year":"2001","unstructured":"Thunberg U  et al (2001) CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 97(6):1892\u20131894","journal-title":"Blood"},{"issue":"10","key":"11_CR21","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/leu.2016.88","volume":"30","author":"M Dal Bo","year":"2016","unstructured":"Dal Bo M  et al (2016) CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia 30(10):2011\u20132018","journal-title":"Leukemia"},{"issue":"9","key":"11_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","volume":"32","author":"P Bulian","year":"2014","unstructured":"Bulian P  et al (2014) CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 32(9):897\u2013904","journal-title":"J Clin Oncol"},{"issue":"2","key":"11_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","volume":"111","author":"V Gattei","year":"2008","unstructured":"Gattei V  et al (2008) Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111(2):865\u2013873","journal-title":"Blood"},{"issue":"1","key":"11_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cyto.b.21384","volume":"94","author":"CE Gooden","year":"2018","unstructured":"Gooden CE  et al (2018) CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Cytomet B Clin Cytom 94(1):129\u2013135","journal-title":"Cytomet B Clin Cytom"},{"issue":"15","key":"11_CR25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1182\/blood.2019003179","volume":"135","author":"E Tissino","year":"2020","unstructured":"Tissino E  et al (2020) CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood 135(15):1244\u20131254","journal-title":"Blood"},{"issue":"18","key":"11_CR26","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","volume":"29","author":"A Alsadhan","year":"2023","unstructured":"Alsadhan A  et al (2023) CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clin Cancer Res 29(18):3612\u20133621","journal-title":"Clin Cancer Res"},{"issue":"1","key":"11_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood.V98.1.29","volume":"98","author":"AC Rawstron","year":"2001","unstructured":"Rawstron AC  et al (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98(1):29\u201335","journal-title":"Blood"},{"issue":"9","key":"11_CR28","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher S  et al (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30(9):980\u2013988","journal-title":"J Clin Oncol"},{"issue":"31","key":"11_CR29","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","volume":"34","author":"G Kovacs","year":"2016","unstructured":"Kovacs G  et al (2016) Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol 34(31):3758\u20133765","journal-title":"J Clin Oncol"},{"issue":"13","key":"11_CR30","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P  et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23(13):2971\u20132979","journal-title":"J Clin Oncol"},{"issue":"4","key":"11_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T  et al (2024) Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med 390(4):326\u2013337","journal-title":"N Engl J Med"},{"issue":"2","key":"11_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41571-023-00858-8","volume":"21","author":"D Romero","year":"2024","unstructured":"Romero D (2024) Benefit with MRD-guided treatment in CLL. Nat Rev Clin Oncol 21(2):84","journal-title":"Nat Rev Clin Oncol"},{"key":"11_CR33","unstructured":"Stetler-Stevenson M et al (2007) Clinical flow cytometric analysis of neoplastic hematolymphoid cells; approved guideline (CLSI H43). Clinical and Laboratory Standards Institute, Wayne, Pennsylvania"},{"issue":"5","key":"11_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/(SICI)1097-0320(19971015)30:5<214::AID-CYTO2>3.0.CO;2-H","volume":"30","author":"GT Stelzer","year":"1997","unstructured":"Stelzer GT  et al (1997) U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5):214\u2013230","journal-title":"Cytometry"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.btre.2015.04.004","volume":"7","author":"D Cadena-Herrera","year":"2015","unstructured":"Cadena-Herrera D  et al (2015) Validation of three viable-cell counting methods: manual, semi-automated, and automated. Biotechnol Rep (Amst) 7:9\u201316","journal-title":"Biotechnol Rep (Amst)"},{"issue":"1","key":"11_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","volume":"27","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC  et al (2013) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27(1):142\u2013149","journal-title":"Leukemia"},{"issue":"3","key":"11_CR37","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.V92.3.946","volume":"92","author":"B Gu","year":"1998","unstructured":"Gu B, Bendall LJ, Wiley JS (1998) Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92(3):946\u2013951","journal-title":"Blood"},{"issue":"2","key":"11_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1158\/1078-0432.CCR-13-1993","volume":"20","author":"A Vardi","year":"2014","unstructured":"Vardi A  et al (2014) IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications. Clin Cancer Res 20(2):323\u2013330","journal-title":"Clin Cancer Res"},{"issue":"6","key":"11_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3324\/haematol.2017.186684","volume":"103","author":"F Autore","year":"2018","unstructured":"Autore F  et al (2018) Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica 103(6):931\u2013938","journal-title":"Haematologica"},{"issue":"4","key":"11_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cyto.b.21953","volume":"100","author":"JM Goshaw","year":"2021","unstructured":"Goshaw JM  et al (2021) 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL\/SLL. Cytometry B Clin Cytom 100(4):509\u2013518","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"11_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cyto.a.24507","volume":"101","author":"R Carsetti","year":"2022","unstructured":"Carsetti R  et al (2022) Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions. Cytometry A 101(2):131\u2013139","journal-title":"Cytometry A"},{"issue":"1","key":"11_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/cei.12149","volume":"174","author":"S Agrawal","year":"2013","unstructured":"Agrawal S  et al (2013) Transitional B cell subsets in human bone marrow. Clin Exp Immunol 174(1):53\u201359","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"11_CR43","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1002\/cpz1.503","volume":"2","author":"Q Gao","year":"2022","unstructured":"Gao Q, Roshal M (2022) Minimal\/measurable disease analysis in chronic lymphocytic leukemia\/small lymphocytic lymphoma by flow cytometry. Curr Protoc 2(8):e503","journal-title":"Curr Protoc"}],"container-title":["Methods in Molecular Biology","Immunophenotyping"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5607-5_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:51Z","timestamp":1790754411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5607-5_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"ISBN":["9781071656068","9781071656075"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5607-5_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}